From: Low dose Naltrexone for induction of remission in inflammatory bowel disease patients
General characteristics | |||||
 Diagnosis, N (%) | UC, 19 (40%) | CD, 28 (60%) | Combined, 47 | ||
 Gender (M/F) | 10/9 | 9/19 | 19/28 | ||
 Median age at diagnosis (years, IQR) | 31 (27–44.5) | 23 (16.8–32.5) | 27 (18–39.5) | ||
 Median age at start of LDN (years, IQR) | 42 (33.5–52) | 35.5 (25.5–53.5) | 40 (27.5–52.5) | ||
 Median disease duration at start of LDN (years, IQR) | 6.9 (3.2–12.4) | 7.8 (3.8–16.5) | 7.0 (3.8–13.4) | ||
 CRP mg/L, median (IQR) | 7 (2–27) | 6 (2–7) | 6 (2–9) | ||
 Endoscopic score (median, IQR) | 2.0 (1.0–2.0) | 2.0 (2.0–2.0) | 2.0 (1.25–2.0) | ||
Disease characteristics | |||||
 Disease extent or phenotype [montreal classification, % (N)] | E1 | 11% (2) | L1 | 7% (2) |  |
E2 | 63% (12) | L2 | 32% (9) | ||
E3 | 26% (5) | L3 | 61% (17) |